1,4-Diazepan-6-ol → 1-(6-(6-(5-cyclopropylpyridin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)pyridin-2-yl)-1,4-diazepan-6-ol
反応式
[CH:1]1([C:4]2[CH:5]=[C:6]([C:10]3[N:15]=[CH:14][C:13]4[CH:16]=[N:17][N:18]([C:19]5[CH:24]=[CH:23][CH:22]=[C:21](F)[N:20]=5)[C:12]=4[CH:11]=3)[CH:7]=[N:8][CH:9]=2)[CH2:3][CH2:2]1.[NH:26]1[CH2:32][CH:31]([OH:33])[CH2:30][NH:29][CH2:28][CH2:27]1>>[CH:1]1([C:4]2[CH:5]=[C:6]([C:10]3[N:15]=[CH:14][C:13]4[CH:16]=[N:17][N:18]([C:19]5[N:20]=[C:21]([N:26]6[CH2:32][CH:31]([OH:33])[CH2:30][NH:29][CH2:28][CH2:27]6)[CH:22]=[CH:23][CH:24]=5)[C:12]=4[CH:11]=3)[CH:7]=[N:8][CH:9]=2)[CH2:3][CH2:2]1参加物
3
実験手順
Following the procedures as described in EXAMPLE 8 and starting with 6-(5-cyclopropylpyridin-3-yl)-1-(6-fluoropyridin-2-yl)-1H-pyrazolo[4,3-c]pyridine and 1,4-diazepan-6-ol, 115 was obtained as an off-white solid (25.1 mg, 17%). 1H NMR (400 MHz, DMSO) δ 9.31-9.27 (s, 1H), 9.07-9.00 (dd, J=16.3, 6.5 Hz, 2H), 8.65-8.59 (d, J=5.6 Hz, 1H), 8.48-8.44 (t, J=2.8 Hz, 1H), 8.09-8.03 (t, J=2.0 Hz, 1H), 7.73-7.67 (t, J=8.1 Hz, 1H), 7.20-7.14 (d, J=7.7 Hz, 1H), 6.73-6.68 (d, J=8.5 Hz, 1H), 4.82-4.73 (s, 1H), 4.03-3.87 (m, 3H), 3.74-3.57 (m, 2H), 3.02-2.93 (t, J=5.4 Hz, 2H), 2.87-2.75 (dd, J=13.8, 3.8 Hz, 1H), 2.70-2.60 (dd, J=13.8, 5.9 Hz, 1H), 2.15-2.03 (m, 1H), 1.10-1.02 (m, 2H), 0.92-0.82 (m, 2H); MS (ESI) m/z: 428.2 [M+H]+